Longitudinal amyloid imaging using 11C-PiB: Methodologic considerations

Journal of Nuclear Medicine

Volumn 54, Issue 9, 2013, Pages 1570-1576

  Van Berckel, Bart N M ^a   Ossenkoppele, Rik ^a,b   Tolboom, Nelleke ^a,b   Yaqub, Maqsood ^a   Foster Dingley, Jessica C ^a   Windhorst, Albert D ^a   Scheltens, Philip ^b   Lammertsma, Adriaan A ^a   Boellaard, Ronald ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer disease; Positron emission tomography; Receptor parametric mapping; Reference Logan; SUVr

Indexed keywords

AMYLOID; PITTSBURGH COMPOUND B; AMYLOID BETA PROTEIN; BENZOTHIAZOLE DERIVATIVE; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; BRAIN CORTEX; CEREBELLUM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; GRAY MATTER; HUMAN; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RELIABILITY; SIMULATION; 11C-PITTSBURGH COMPOUND-B; AGED; BRAIN; FEMALE; LONGITUDINAL STUDY; MALE; METABOLISM; METHODOLOGY; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTOR PARAMETRIC MAPPING; REFERENCE LOGAN; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SUVR; TISSUE DISTRIBUTION;

11C-PITTSBURGH COMPOUND-B; ALZHEIMER DISEASE; POSITRON EMISSION TOMOGRAPHY; RECEPTOR PARAMETRIC MAPPING; REFERENCE LOGAN; SUVR;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BENZOTHIAZOLES; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84887378502     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.113654     Document Type: Article

References (31)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
2. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
3. Tolboom N, Yaqub M, van der Flier WM, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med. 2009;50:191-197.
4. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856-2866.
5. Ossenkoppele R, Tolboom N, Foster-Dingley JC, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2012;39:990-1000.
6. Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009; 73:1186-1192.
7. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MR imaging in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355-1365.
8. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-372.
9. Villain N, Chetelat G, Grassiot B, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126-2139.
10. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
11. Yaqub M, Tolboom N, Boellaard R, et al. Simplified parametric methods for [11C]PIB studies. Neuroimage. 2008;42:76-86.
12. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
13. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-1283.
14. Carson RE, Channing MA, Blasberg RG, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24-42.
15. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. J Nucl Med. 1997;38:1614-1623.
16. Svarer C, Madsen K, Hasselbalch SG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24:969-979.
17. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279-287.
18. Wu Y, Carson R. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood FlowMetab. 2002;22:1440-1452.
19. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959-1972.
20. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol. 1989;77:314-319.
21. Koeppe RA, Holden JE, Ip WR. Performance comparison of parameter estimation techniques for the quantification of local cerebral blood flow by dynamic positron computed tomography. J Cereb Blood Flow Metab. 1985;5:224-234.
22. Tolboom N, YaqubM, Boellaard R, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009;36:1629-1638.
23. Yaqub M, Boellaard R, Kropholler MA, Lammertsma AA. Optimization algorithms and weighting factors for analysis of dynamic PET studies. Phys Med Biol. 2006;51:4217-4232.
24. Nelissen N, Van LK, Thurfjell L, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251-1259.
25. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-920.
26. Slifstein M, Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med. 2000;41:2083-2088.
27. Zhou Y, Sojkova J, Resnick SM, Wong DF. Relative equilibrium plot improves graphical analysis and allows bias correction of standardized uptake value ratio in quantitative 11C-PiB PET studies. J Nucl Med. 2012;53:622-628.
28. Alegret M, Cuberas-Borros G, Vinyes-Junque G, et al. A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis. 2012;30:109-120.
29. Bremmer JP, van Berckel BN, Persoon S, et al. Day-to-day test-retest variability of CBF, CMRO2, and OEF measurements using dynamic 15O PET studies. Mol Imaging Biol. 2011;13:759-768.
30. Sperling RA, Salloway S, Raskind M, et al., on behalf of the Bapineuzumab Study 302 Investigators. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E e4 carriers. http://www2.kenes.com/ efns/info/Documents/ Sperling-Bapineuzumab%20IV%20Study%20302- EFNS%20Presentation%20Slides-9-11-2012.pdf. Accessed August 5, 2013.
31. Koeppe RA, Frey KA. Equilibrium analysis of [11C]PIB studies. Neuroimage. 2008;41:T30.